ArticleBreast (Edinburgh, Scotland)2022
Locally advanced breast cancer.
Article in Breast (Edinburgh, Scotland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Oncological outcomes following extreme oncoplastic breast conserving surgery (eOPBCS) for locally advanced breast cancer (LABC): A systematic review and meta-analysis.Breast (Edinburgh, Scotland) · 2025Pooled it
- Locally advanced breast cancer patients should be cautious about the immediate breast reconstruction after mastectomy: a pooling analysis of safety and efficacy.World journal of surgical oncology · 2024Pooled it
- The use of Hybrid Techniques in Whole-Breast Radiotherapy: A Systematic Review.Technology in cancer research & treatmentPooled it
- Multidisciplinary Management of Complicated Locally Advanced and Fungating Breast Cancer: A Narrative Review.Cancers · 2026Review
- Apparent diffusion coefficient and intravoxel incoherent motion-derived true diffusion serve as early non-contrast longitudinal biomarkers of neoadjuvant chemotherapy response.Scientific reports · 2026Article
- Barriers to surgical treatment and diagnostic intervals among women with operable breast cancer in Benin: a retrospective study from two referral centers (2019-2023).World journal of surgical oncology · 2026Article
- Profiles of microRNAs in Patients with Advanced Breast Cancer Who are Chemoresistant or Chemosensitive to Fluorouracil, Adriamycin, and Cyclophosphamide Treatment.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Advances in locoregional surgical treatment ofFrontiers in oncology · 2026Review
- Early tumour size changes from neoadjuvant chemotherapy as a predictor of pathologic response in breast cancer.PloS one · 2026Article
- Efficacy of AC-T Versus TAC Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Retrospective Analysis.International journal of breast cancer · 2026Article
- Trends in Surgical Treatment for cT4 Breast Cancer After Neoadjuvant Systemic Therapy: A Nationwide Study in The Netherlands.Annals of surgical oncology · 2025Article
- Deciphering key chemotherapeutic drug targets within tyrosine metabolism for breast cancer and advancing a wide-ranging diagnostic strategy.Discover oncology · 2025Article
- Relationship Between [European journal of breast health · 2025Article
- Observational
- Rare diagnosis of locally advanced triple‑negative breast cancer with paraneoplastic dermatomyositis: A case report and literature review.Oncology letters · 2025Article
- Factors associated with locoregional recurrence after neoadjuvant chemotherapy for breast cancer in a safety-net medical center.Breast cancer research and treatment · 2025Article
- Investigating the optimal timing for the ultrasound prediction of a pathologic complete response in neoadjuvant breast cancer treatment.Quantitative imaging in medicine and surgery · 2025Article
- Article
- Article
- Optimizing treatment sequence for inoperable locally advanced breast cancer: Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a real-world setting.International journal of cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Locally advanced breast cancer (LABC) is defined here as inoperable breast adenocarcinoma without distant metastases. Patients with LABC require a multidisciplinary approach. Given the risk of distant metastasis, staging exams are necessary. The incidence of LABC (stages IIIB and IIIC) has decreased in recent years. LABC has rarely been investigated separately: patients with LABC have participated both in clinical trials of palliative and of neoadjuvant therapy. Most trials did not analyze responses and long-term outcomes independently; thus, the treatment of patients with LABC is extrapolated from studies of patients with less or more advanced disease. Pathologic confirmation and molecular profiling are essential for the choice of neoadjuvant chemotherapy. Preoperative endocrine therapy may be considered in certain clinical situations; the addition of a CDK4/6 inhibitor is being investigated. HER2 positive LABCs are targeted with anti-HER2 agents combined with chemotherapy. PD-1 and PD-L1 antibodies in 'triple-negative' LABC are promising. Excellent responses to neoadjuvant therapy enable conservative surgery in many patients; however, inflammatory breast cancer may still indicate mastectomy. Postoperative radiotherapy is usually indicated. Target volumes include breast/chest wall, axillary, supraclavicular and internal mammary nodal basins. Preoperative radiation therapy can be useful in patients without response to systemic therapies. Palliative surgery for poor responders after neoadjuvant systemic and radiation therapy can be considered. Multidisciplinary teams can optimize local control and prevent relapses. However, modest improvement in survival was achieved between 2000 and 2014 underscoring the unmet need in patients with LABC who will benefit from specific research efforts in this disease entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.